No headlines found.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Globe Newswire (Tue, 7-May 8:00 AM ET)
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Traws Pharma trades on the NASDAQ stock market under the symbol TRAW.
As of May 10, 2024, TRAW stock price declined to $0.63 with 22,843 million shares trading.
TRAW has a market cap of $15.94 million. This is considered a Sub-Micro Cap stock.
TRAW support price is $.62 and resistance is $.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRAW stock will trade within this expected range on the day.